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Abstract
Background: As the survival of castration‐resistant prostate cancer (CRPC) remains
poor, and the nuclear factor‐κB (NF‐κB) pathways play key roles in prostate cancer
(PC) progression, several studies have focused on inhibiting the NF‐κB pathway
through generating inhibitory κB kinase subunit α (IKKα) small molecule inhibitors.
However, the identification of prognostic markers able to discriminate which patients
could benefit from IKKα inhibitors is urgently required. The present study investigated
the prognostic value of IKKα, IKKα phosphorylated at serine 180 (p‐IKKα S180) and
threonine 23 (p‐IKKα T23), and their relationship with the androgen receptor (AR) and
Ki67 proliferation index to predict patient outcome.
Methods: A cohort of 115 patients with hormone‐naïve PC (HNPC) and CRPC
specimens available were used to assess tumor cell expression of proteins within
both the cytoplasm and the nucleus by immunohistochemistry. The expression levels
were dichotomized (low vs high) to determine the associations between IKKα, AR,
Ki67, and patients'Isurvival. In addition, an analysis was performed to assess po-
tential IKKα associations with clinicopathological and inflammatory features, and
potential IKKα correlations with other cancer pathways essential for CRPC growth.
Results: High levels of cytoplasmic IKKα were associated with a higher cancer‐
specific survival in HNPC patients with low AR expression (hazards ratio [HR], 0.33;
95% confidence interval [CI] log‐rank, 0.11‐0.98; P = .04). Furthermore, nuclear IKKα
(HR, 2.60; 95% CI, 1.27‐5.33; P = .01) and cytoplasmic p‐IKKα S180 (HR, 2.10; 95%
CI, 1.17‐3.76; P = .01) were associated with a lower time to death from recurrence in
patients with CRPC. In addition, high IKKα expression was associated with high
levels of T‐cells (CD3+ P = .01 and CD8+ P = .03) in HNPC; however, under castra-
tion conditions, high IKKα expression was associated with high levels of CD68+
macrophages (P = .04), higher Gleason score (P = .01) and more prostate‐specific
antigen concentration (P = .03). Finally, we identified crosstalk between IKKα and
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members of the canonical NF‐κB pathway in the nucleus of HNPC. Otherwise, IKKα
phosphorylated by noncanonical NF‐κB and Akt pathways correlated with members
of the canonical NF‐κB pathway in CRPC.
Conclusion: The present study reports that patients with CRPC expressing high
levels of nuclear IKKα or cytoplasmic p‐IKKα S180, which associated with a lower
time to death from recurrence, may benefit from IKKα inhibitors.
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1 | INTRODUCTION
Prostate cancer (PC) remains the most commonly diagnosed non‐
cutaneous malignancy in men and the second most common cause of
cancer death worldwide.1,2 Active surveillance, radical prosta-
tectomy, brachytherapy, and external beam radiotherapy are cur-
rently the most common treatments for localized PC.3 However,
androgen deprivation therapy (ADT) and/or chemotherapies are the
most indicated remedy to treat advanced or metastatic PC.4 Ninety
percent of patients have remission of the disease, which always de-
velops into castration‐resistant prostate cancer (CRPC) within 2 to 3
years.5 Metastatic CRPC associates with poor prognosis and the
mean survival time is approximately 18 months.6 As androgen re-
ceptor (AR) signaling is the main driver of PC cell proliferation and
survival, understanding ADT resistance mechanisms and new ad-
juvant therapies are required to improve patient survival. Some of
these mechanisms have been explained during the last few years.7 As
prostate cells are androgen‐dependent, the absence of androgens
leads to apoptotic cell death, which promotes inflammation sur-
rounding the tumor, which is related to the constitutive activation
of the nuclear factor kappa‐light‐chain‐enhancer of the activated
B cell (nuclear factor‐κB [NF‐κΒ]) pathway.8 The NF‐KΒ family
comprises five proteins‐ RelA/p65, NFKB1/p50, c‐Rel, RelB, and
NF‐κΒ 2/p52. In absence of stimulus, these proteins reside in the
cytoplasm forming homo‐ or heterodimers and typically are bound to
an inhibitory protein (inhibitor of KBs). Under the stimulus, NF‐κBs
are activated via one of two cascades (canonical and noncanonical).
Briefly, canonical NF‐κB signaling is activated by the cytoplasmic
inhibitory κ‐B kinase (IKK) complex composed of IKK subunits α and
β (IKKα and IKKβ) and the regulatory subunit NF‐κB essential mod-
ulator (NEMO or IKKγ). Upon stimulation, the IKK complex catalyzes
the phosphorylation of IKBα in a manner that is dependent on IKKβ.
This results in the targeted degradation of IKBα and the release of
the p65‐p50 dimer to accumulate in the nucleus. On the other hand,
IKKα homodimers and nuclear factor KB‐inducing kinase (NIK) are
the main drivers for the activation of the noncanonical NF‐κB path-
way. Following their activation, the RelB‐p100 heterodimer is
processed to RelB‐p52.9,10 The upregulation of the noncanonical
NF‐κB subunit p52 has been described as important in PC.
For example, Lessard et al reported RelB‐p52 dimers are more ex-
pressed in PC cores than the canonical NF‐κB subunits RelA and p50.
In addition, the number of nuclear RelB‐positive cores was corre-
lated with higher Gleason scores, suggesting the role of non-
canonical NF‐κB subunits in the progression of PC.11 Furthermore,
they reported that androgenic stimulation of LNCaP cells (androgen‐
sensitive cells) with the androgen analog R1881positively regulates
the noncanonical NF‐κB pathway as p52 accumulates both in the
nucleus and the cytoplasm.12 Hence, Nadimity et al demonstrated
that the overexpression of the p52 subunit was implicated in
castration‐resistant growth by inhibiting LNCaP cell cycle arrest and
apoptosis in the androgen‐deprived condition in vitro and inducing
LNCaP cell growth in castrated nude mice in vivo. Furthermore, this
was accompanied by continued expression and activation of the AR,
providing evidence that p52 may activate AR during CRPC devel-
opment.13 Subsequently, Nadimity et al exhibited that RelB‐p52 with
AR gene coactivators induce the aberrant activation of AR. In ad-
dition, they proved that the knockdown of p52 reduce AR activity in
LNCaP cells.14 Furthermore, they showed that several genes in-
volved in cell growth, proliferation, and movement were potential
targets of RelB/p52.15 Collectively, these findings suggest a role
for RelB/p52 in the progression of CRPC. More importantly, the
resistance to next‐generation anti‐androgens (enzalutamide) was
associated with AR and AR splice variants activation derived from an
increase of RelB/p52 expression.16,17 Targeting the noncanonical
NF‐κΒ pathway could, therefore, offer a new treatment paradigm for
PC in combination with ADT.
NIK and IKKα are current therapeutic targets under investiga-
tion in the noncanonical NF‐κΒ pathway due to their crucial role in
processing p100 to p52.18 In PC, IKKα‐focused studies emphasized
its function in controlling invasiveness, metastasis and inflammation,
suggesting the therapeutic potential of IKKα inhibition.19‐21 For ex-
ample, IKKα inhibition by using synthetic small interference RNAs
confirmed its major role in PC invasion and metastasis.19 In addition,
a few studies implicate IKKα in cancer cell proliferation. Karin et al
determined epithelial proliferation being regulated by IKKα,22
although this study was on breast cancer (BCa). In PC, Shukla et al
examined the effect of inhibiting IKKα by using apigenin and de-
monstrated antiproliferative and anti‐invasive effects.20
Despite many reports in the literature describing the develop-
ment of IKKβ inhibitors (subsequently abandoned because of reports
of target‐related toxicity18), potent and selective IKKα inhibitors with
in vivo activity remain unknown. Although we have made some
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progress in this respect23 and a IKKα clinical candidate(s) should
emerge from our work, the discovery of prognostic markers able to
identify which patients could benefit from this therapy is urgently
required. Previously, we have demonstrated that high IKKα expres-
sion was associated with reduced time to recurrence (TTR) and
cancer specific survival (CSS) in estrogen receptor positive BCa.24
This study aims to assess whether combining IKKα expression and
stratification of patients according to their AR status can predict
those likely to respond to combination therapy of ADT and an IKKα
inhibitor. Furthermore, since as little is known about the involvement
of IKKα in PC cell proliferation, and its function has been seen more
related to invasive and metastatic capacities,19 we assessed the as-
sociation between proliferative index Ki67 and IKKα as well as its
prognostic value during the progression to CRPC.
2 | MATERIALS AND METHODS
2.1 | Patient cohort and sample collection
A total of 115 patients were included in this study, diagnosed between
1984 to 2000 at the Edinburgh Western General Hospital, Glasgow
Royal Infirmary Hospital and Kilmarnock Crosshouse Hospital.
Patients who initially responded to androgen ablation treatment
(sub‐capsular bilateral orchidectomy or LHRH agonists combined with
anti‐androgens) and subsequently relapsed (two consecutive rises in
prostate‐specific antigen [PSA] >10%) were included in the study. All
selected patients had both hormone‐naïve PC (HNPC) specimens gath-
ered via trans‐rectal ultrasound guided biopsies and CRPC specimens
gathered via transurethral resection of the prostate to relieve bladder
outflow obstruction available. Information relating to clinical diagnosis,
treatment and outcome was obtained from the pathology notes including
age (median 70 years, interquartile range (IQR), 66‐74), PSA at diagnosis
(median, 34.5 ng/mL; IQR, 9‐126), PSA at recurrence (median 16ng/mL;
IQR, 5‐39), Gleason score at diagnosis (median score 7.5; IQR, 6‐9),
Gleason score at recurrence (median score 9; IQR, 8‐9), time to relapse
from diagnosis (TTR median 2.6 years; IQR, 1.6‐4.3), time to death from
relapse (TTDR median 2.2 years. IQR 1.0‐3.6) and CSS (median 5.5 years;
IQR, 3.4‐7.3). The study was approved by the Multicentre Research
Ethics Committee from Scotland (MREC/01/0/36) and Local Research
and Ethical Committees.
2.2 | Immunohistochemistry
IHC was performed on 4 μm sections to assess total IKKα, IKKα
phosphorylated at serine 180 (p‐IKKα S180) and threonine 23
(p‐IKKα T23). IHC for IKKβ, NEMO, Akt phosphorylated at the serine
473 (p‐Akt S473), Ki67 and AR had previously been performed in this
cohort. Slides were deparaffinised with xylene and rehydrated though a
series of graded alcohols. Heat‐induced antigen retrieval was per-
formed using citrate buffer pH 6 (Vector Laboratories, CA) under
pressure for 5minutes. Endogenous peroxidase activity was blocked
using 3% (vol/vol) hydrogen peroxide and nonspecific background
staining was blocked using 5% (vol/vol) horse serum in Tris‐buffered
saline for 20minutes. Total IKKα (Cat GWB‐662250; Genway), p‐IKKα
S180 (Cat ab138426; Abcam) and p‐IKKα T23 (Cat ab38515; Abcam)
primary antibodies were used. Slides were then incubated in these
primary antibodies overnight at 4°C; with the following antibody con-
centrations: total IKKα at 1:1000, p‐IKKα S180 at 1:200, and p‐IKKα
T23 at 1:200. Envision (Dako) was added to the sections for 30minutes
at room temperature then slides where visualized using DAB substrate.
Harris Haematoxylin counterstaining was performed then slides were
dehydrated and mounted using a distrene, plasticizer, xylene.
2.3 | Scoring method
Stained sections were scanned using a Hamamatsu NanoZoomer
(Welwyn Garden City, Hertfordshire, UK) at ×20 magnification, and
visualization was carried out using Slidepath Digital Image Hub,
version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK).
Cytoplasmic and nuclear protein staining were assessed separately.
Slides were scored by two independent observers using the weighted
histoscore method, and the interclass correlation coefficient was
greater than 0.7 for all antibodies.25 If a difference of more than 50
weighted histoscore units was observed, the core was re‐scored by
both observers independently, in the majority of the cases this re-
solved any differences in scores, however, if there still remained a
difference, both observers discussed the case and reached a con-
sensus. The weighted histoscore is calculated using the following
equation: 0 × (% cells not stained) + 1 × (% cells weakly stained) + 2
× (% cells moderately stained) + 3 × (% cells strongly stained). This
gives a range of scores from 0 to 300. Ki67 was assessed using a
point count and <1% considered high expression.
2.4 | Assessment of the local inflammatory
infiltration
The number of T‐lymphocytes (CD3+, CD8+, and FOXP3+) and
macrophages (CD68+ was determined by IHC for this cohort using
the following antibodies: CD3 (Cat RM‐9107‐S, 1:1000; Thermo
Fisher Scientific), CD8 (Cat Clone C8/114B, 1:200; Dako), FOXP3
(Cab22510, 1:100; Abcam) and CD68 (Cat M0876, 1:200; Dako).
Briefly, the density for each immune cell subtype was evaluated and
the immune infiltration was graded as absent, weak, moderate or
strong using a semi‐quantitative method.
2.5 | Statistical analysis
Statistics were performed using the SPSS version 25.0 (IBM, Armonk,
NY) and P values of less than .05 were considered statistically sig-
nificant. Cut‐off values to dichotomize each protein into low and high
expression were determined using receiver operating characteristic
MONTES ET AL. | 3
analysis. The relationship between protein expression and TTR, TTDR,
and CSS was determined using Kaplan‐Meier survival curves and dif-
ferences compared using the log‐rank test. Hazard ratio (HR) and 95%
confidence interval (CI) values were calculated using univariate cox
regression survival analysis. The associations between IKKα and clin-
icopathological characteristics, inflammation features or activated AR
signaling was examined using the χ2 test for linear trend. Correlations
between IKKα and PC‐deregulated pathways were conducted using the
non‐parametric Spearman's rank test. Multivariate cox regression sur-
vival analysis using a backward conditional elimination model and a
statistical significance threshold of P value less than .05 was performed
to identify independent prognostic biomarkers.
3 | RESULTS
3.1 | Patient characteristics
We analyzed 115 patients that progressed from HNPC to CRPC to
investigate IKKα and AR as biomarkers for combination therapy
(Table 1). Forty‐eight percent of patients were younger than 70 years
of age and 41% patients had a high proliferation rate for HNPC, and
this increased to 50% with progression to CRPC. Similarly, for
Gleason grade, 45% patients had a high tumor grade for HNPC, and
this increased to 78% with progression to CRPC. Conversely, PSA
concentration decreased during the transition to CRPC, 60% patients
had a high PSA concentration for HNPC, and this decreased to 28%
with progression to CRPC. Median follow‐up was 4.9 years (IQR,
3.3‐7.0) with 68 cancer and 40 non‐cancer deaths. All patients pre-
sented biochemical relapse (TTR median 2.6 years; IQR, 1.6‐4.3).
3.2 | The molecular prognostic profile differed
between HNPC and CRPC
We investigated the associations between AR, Ki67, total IKKα,
p‐IKKα S180, p‐IKKα T23 and TTR, TTDR, or CSS during the transition
from HNPC to CRPC (Table 2). Ki67 proliferation rate and CSS were
associated at the time of diagnosis (HR, 2.5; 95% CI, 1.2‐5.0; P = .01);
patients with HNPC presenting high Ki67 expression were associated
with significantly shorter CSS. However, following transition to CRPC,
high Ki67 expression associated with shorter TTDR (HR, 2.6; 95% CI,
1.3‐5.2; P = .01) with patients with a high Ki67 having a reduced 2‐year
TTDR of 46% compared with 69% for those with low Ki67. In addition,
high levels of cytoplasmic p‐IKKα S180 (HR, 2.10; 95% CI, 1.17‐3.76;
P = .01) and nuclear IKKα (HR, 2.60; 95% CI, 1.27‐5.33; P = .01) were
associated with significantly shorter TTDR.
3.3 | The prognostic effect of cytoplasmic IKKα was
associated with low AR expression in HNPC but not
CRPC patients
As IKKα has a role in the transition from HNPC to CRPC by en-
hancing the expression of genes transcribed by AR,13,14 we stratified
patients based on their AR protein expression. In HNPC, patients
with high levels of cytoplasmic IKKα and low AR expression asso-
ciated with greater CSS (HR, 0.33; 95% CI, 0.11‐0.98; log‐rank
P = .04, Figure 1B). Conversely, cytoplasmic IKKα expression was not
associated with survival in the full cohort (HR, 0.72; 95% CI, 0.36‐
1.43; log‐rank P = .34; Figure 1A) or patients with high AR expression
(HR, 3.37; 95% CI, 0.95‐12.04; log‐rank P = .05; Figure 1C). Fur-
thermore, a lower expression of cytoplasmic IKKα was strongly as-
sociated with >10 ng/mL PSA in the full cohort (P ≤ .001) as shown in
Table 3. In CRPC, no associations were seen in low or high AR ex-
pressed patients for cytoplasmic or nuclear IKKα (Table S2).
3.4 | Patient stratification based on their Ki67
proliferation rate enhanced the prognostic effect of
IKKα phosphorylation at S180 and T23
As high proliferative index Ki67 is associated with poorer PC survival26
and IKKα suppression possesses an antiproliferative effect,20 we in-
vestigated the association of IKKα and patient outcome in patients
stratified for low and high Ki67. In HNPC (Table S1), high cytoplasmic
p‐IKKα S180 associated with better CSS in patients with high Ki67
(HR, 0.8; 95% CI, 0.2‐4.1; P = .02). No associations were seen for any
TABLE 1 Overview of patients' characteristics (n = 115)
Clinicopathological parameters N (%) Median (IQR)
Age (<70/>70/unknown) 55 (48)/10 (9)/48 (42)/2 (2) 70 (66‐74)
Gleason at diagnosis (<7/7/>7/unknown) 28 (24)/24 (21)/52 (45)/11 (10) 7.5 (6‐9)
Gleason at recurrence (<7/7/>7/unknown) 5 (4)/12 (10)/90 (78)/8 (7) 9 (8‐9)
PSA at diagnosis (≤10 ng/mL/>10 ng/mL/unknown) 29 (25)/69 (60)/17 (15) 34.5 (9‐126)
PSA at recurrence (≤10 ng/mL/>10 ng/mL/unknown) 26 (23)/32 (28)/57 (50) 16 (5‐39)
Ki67 at diagnosis (≤1% cells/>1% cells/unknown) 14 (12)/47 (41)/54 (47) 3.0 (1.0‐6.5)
Ki67 at recurrence (≤1% cells/>1% cells/unknown) 11 (10)/58 (50)/46 (40) 8.0 (3.0‐16.0)
Abbreviations: IQR, interquartile range; PSA, prostate‐specific antigen.
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other markers in patients with HNPC. In CRPC (Table S2), high
expression of nuclear p‐IKKα T23 was associated with better CSS (HR,
0.1; 95% CI, 0.01‐0.8; P = .007; Figure 2B) and greater TTDR (HR, 0.1;
95% CI, 0.02‐1.3; P = .04; Figure 3B) in patients expressing low Ki67.
However, no significant associations were seen for the full cohort
(Figures 2A and 3A) or patients with high Ki67 (Figures 2C and 3C).
No associations were seen for any other markers for CRPC.
3.5 | IKKα associated with markers of adaptive
immunity in HNPC but innate immunity in CRPC
As IKKα is involved in PC progression and CRPC growth due its in-
teractions with inflammatory modulators and AR signaling,27,28 we
investigated associations between total IKKα, p‐IKKα S180 or p‐IKKα
T23, and clinicopathological parameters and inflammatory regulators
(Table 3). For HNPC, low total cytoplasmic IKKα associated with in-
creased PSA levels (P = .001), and high cytoplasmic p‐IKKα T23 asso-
ciated with a strong CD3+ (P = .01) and CD8+ (P = .03) lymphocytic
infiltration. No associations where seen for nuclear expression. For
CRPC, high total cytoplasmic IKKα was associated with strong CD68+
macrophage infiltration (P = .04) whereas high cytoplasmic p‐IKKα T23
associated with weak CD3+ lymphocytic infiltration (P = .04). Finally,
high nuclear p‐IKKα T23 associated with increased Gleason score
(P = .01), and high nuclear p‐IKKα S180 associated with increased PSA
levels (P = .03). No associations were seen for total nuclear IKKα.
3.6 | IKKα was correlated with members of the
canonical NF‐kB, PI3/Akt, and AR pathways
As IKKα has been previously seen to interact with members of other
cancer pathways involved in CRPC growth, such as the canonical
NF‐kΒ, PI3K/AKT, and AR pathways,29‐32 we evaluated potential
correlations between total IKKα, p‐IKKα S180, and p‐IKKα T23, and
some of the members of these pathways (Table 4). Total IKKα cor-
related with NEMO (P = .04), and p‐IKKα T23 correlated with AR
(P = .02) in the nucleus of HNPC cells. Otherwise, total IKKα, p‐IKKα
TABLE 2 Associations between androgen receptor, Ki67, total IKKα, p‐IKKα S180, p‐IKKα T23, and survival during the transition from
hormone‐naïve to castration‐resistant prostate cancer (n = 115)
Hormone‐naïve prostate cancer Castration‐resistant prostate cnacer
N (%)
2‐y
CSS (SE) P N (%)
2‐y
TTR (SE) P N (%)
2‐y
CSS (SE) P N (%)
2‐y
TTDR (SE) P
Androgen receptor .38 .07 .06 .06
Low 37 (54) 95 (0.04) 36 (54.5) 64 (0.08) 21 (32) 100 (0.00) 19 (30) 71 (0.11)
High 31 (46) 90 (0.06) 30 (45.5) 60 (0.09) 44 (68) 88 (0.05) 44 (70) 42 (0.08)
Ki67 .01* .86 .08 .01*
Low 27 (46) 92 (0.05) 27 (46) 63 (0.09) 24 (36) 91 (0.06) 24 (36) 69 (0.10)
High 32 (54) 94 (0.04) 32 (54) 59 (0.09) 43 (64) 93 (0.04) 42 (64) 46 (0.08)
cIKKα .34 .12 .77 .10
Low 27 (55) 93 (0.05) 25 (52) 68 (0.09) 46 (68) 96 (0.03) 44 (67) 66 (0.07)
High 22 (45) 86 (0.07) 23 (48) 65 (0.10) 22 (32) 86 (0.07) 22 (33) 48 (0.11)
nIKKα .97 .34 .17 .01*
Low 25 (51) 88 (0.07) 23 (48) 65 (0.10) 21 (31) 90 (0.07) 21 (32) 73 (0.10)
High 24 (49) 92 (0.06) 25 (52) 68 (0.09) 47 (69) 94 (0.04) 45 (68) 54 (0.08)
c p‐IKKα S180 .60 .06 .07 .01*
Low 9 (17) 100 (0.00) 9 (17) 67 (0.16) 39 (59) 97 (0.03) 37 (58) 74 (0.08)
High 44 (83) 91 (0.04) 43 (83) 70 (0.07) 27 (41) 89 (0.06) 27 (42) 40 (0.10)
n p‐IKKα S180 .86 .83 .56 .51
Low 27 (51) 93 (0.05) 26 (50) 69 (0.09) 33 (50) 94 (0.04) 32 (50) 67 (0.09)
High 26 (49) 92 (0.05) 26 (50) 69 (0.09) 33 (50) 94 (0.04) 32 (50) 51 (0.09)
c p‐IKKα T23 .99 .67 .31 .85
Low 29 (54) 93 (0.05) 27 (51) 74 (0.08) 38 (54) 95 (0.04) 37 (54) 57 (0.08)
High 25 (46) 92 (0.05) 26 (49) 73 (0.09) 32 (46) 94 (0.04) 31 (46) 62 (0.09)
n p‐IKKα T23 .59 .77 .63 .75
Low 27 (50) 96 (0.04) 27 (51) 74 (0.08) 35 (50) 97 (0.03) 33 (48.5) 66 (0.09)
High 27 (50) 89 (0.06) 26 (49) 73 (0.09) 35 (50) 91 (0.05) 35 (51.5) 54 (0.08)
Abbreviations: c/n, citoplasmic/nulcear; CSS, cancer specific survival; IKK, inhibitory κ‐B kinase; IKKα, IKK subunits α; TTDR, time to death from relapse;
TTR, time to recurrence.
*P ≤ .01.
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F IGURE 1 Cytoplasmic inhibitory κ‐B kinase subunits α (IKKα) associated with good prognosis in high AR‐expressed patients with hormone‐
naïve prostate cancer (HNPC). Kaplan‐Meier plots showing associations between cancer specific survival (CSS) and (A) cytoplasmic IKKα
expression. B, C, Kaplan‐Meier curves showing associations between CSS and cytoplasmic IKKα in (B) low and (C) high patients with androgen
receptor (AR). CI, confidence interval; HR, hazards ratio
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F IGURE 2 Nuclear p‐IKKα T23 is associated with good prognosis in castration‐resistant prostate cancer (CRPC) patients with low Ki67.
A, Kaplan Meier curves showing associations of nuclear p‐IKKα T23 and CSS in the full cohort. B, Kaplan Meier curves showing associations of
nuclear p‐IKKα T23 and CSS in patients with low Ki67. C, Kaplan Meier curves showing associations of nuclear p‐IKKα T23 and CSS in patients
with high Ki67. CI, confidence interval; CRPC, castration‐resistant prostate cancer; CSS, cancer specific survival; HR, hazards ratio; IKK,
inhibitory κ‐B kinase; IKKα, IKK subunits α
MONTES ET AL. | 9
F IGURE 3 Nuclear p‐IKKα T23 is associated with good prognosis in CRPC patients with low Ki67. A, Kaplan Meier curves showing
associations of nuclear p‐IKKα T23 and time to death from relapse (TTDR) in the full cohort. B, Kaplan Meier curves showing associations of
nuclear p‐IKKα T23 and TTDR in patients with low Ki67. C, Kaplan Meier curves showing associations of nuclear p‐IKKα T23 and TTDR in
patients with high Ki67. CI, confidence interval; CRPC, castration‐resistant prostate cancer; HR, hazards ratio; IKK, inhibitory κ‐B kinase; IKKα,
IKK subunits α
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S180 (noncanonical NF‐kB pathway), and p‐IKKα T23 were strongly
correlated with IKKβ (canonical NF‐kB pathway) (P ≤ .001 for all
markers) in the cytoplasm of CRPC cells. Furthermore, cytoplasmic
and nuclear p‐IKKα T23 were correlated with membrane and
cytoplasmic p‐Akt S473, respectively, (P = .03 for both markers).
Finally, total IKKα and IKKβ also correlated in the nucleus of CRPC
cells (P = .01), and cytoplasmic total IKKα correlated with nuclear
NEMO (P = .04). Figure 4 summarizes the crosstalk between IKKα
and the different cancer pathways.
3.7 | IKKα was not an independent prognostic
marker in CRPC
We performed a univariate and multivariate cox regression analysis
to determine the effect of clinicopathological parameters, in-
flammatory features and IKKα expression on patients' survival
(Table 5). As IKKα was not associated with prognosis in the total
cohort in HNPC, we only conducted the analysis for CRPC patients.
Under univariate analysis, PSA (P = .02), Ki67 (P = .01), total nuclear
IKKα (P = .01) and cytoplasmic p‐IKKα S180 (P = .01) were associated
with TTDR and taken forward into multivariate analysis. Under
multivariate analysis, only PSA (P = .05) trended towards significance
for TTDR, neither total nuclear IKKα (P = .11) nor cytoplasmic p‐IKKα
S180 (P = .26) were independent prognostic factors.
4 | DISCUSSION
Many studies associate IKKα with PC cell proliferation, survival, inva-
sion, androgen‐independent growth, and tumor metastasis,13,14,19,21,28,33
suggesting IKKα inhibitors as potential therapeutic agents to treat
localized and advanced PC.18 However, differences in IKKα prognostic
role between HNPC and CRPC are unclear. For this reason, we should
establish prognostic markers able to differentiate which patients will
benefit from IKKα inhibition before starting the treatment. This is the
first study to investigate this concept by determining the prognostic
value of IKKα before and after castration‐resistance as well as its
relationship with AR expression.
We confirm that total cytoplasmic IKKα is a potential good
prognostic marker for HNPC patients with low AR, and it does not
associate with members from the canonical NF‐kB pathway, sug-
gesting that it may be working through the noncanonical pathway.
On the other hand, IKKα is a poor prognostic maker for all CRPC,
with nuclear IKKα and cytoplasmic p‐IKKα S180 associating with
shorter TTDR. In addition, cytoplasmic p‐IKKα S180 correlates with
cytoplasmic IKKβ to drive bad prognosis, suggesting it may be in-
teracting with the canonical NF‐kB pathway in CRPC. Furthermore,
cytoplasmic p‐IKKα T23 associates with increased lymphocytic in-
filtrate in HNPC, whereas total cytoplasmic IKKα associates with
increased macrophages in CRPC. These results suggest that the role
of IKKα changes during the progression to CRPC from protective to
detrimental, potentially due to interactions with inflammatoryT
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infiltrate and whether it is acting via the canonical or noncanonical
NF‐kB pathway.
Assessing the role of IKKα is complex, given its different biolo-
gical functions that are dependent on both cellular type and locali-
zation. Although the activity of cytoplasmic IKKα is associated with
the activation of NF‐kΒ pathways (canonical and noncanonical),
nuclear IKKα has consistently been demonstrated to work
independently in PC.18 Furthermore, IKKα is a substrate for multiple
kinases that phosphorylate it at specific residues. For example, the
phosphorylation of IKKα at S180 is known to take place in the cy-
toplasm by NIK, a prerequisite for activating the noncanonical NF‐kΒ
pathway,34 whereas phosphorylation at T23 is by Akt.35 IKKα can
therefore be activated in response to several signaling pathways,
which, in turn, interact with each other to further complicate IKKα
F IGURE 4 IKKα crosstalk with other members of cancer pathways in the cytoplasm and the nucleus of prostate cancer cells during the
transition from hormone‐naïve to castration‐resistant prostate cancer. A, IKKα crosstalk in hormone‐naïve prostate cancer. Total nuclear IKKα
correlates with nuclear nuclear factor‐κB (NF‐κB) essential modulator (NEMO), and nuclear phosphorylated IKKα at threonine 23 correlates
with nuclear androgen receptor. B, Crosstalk in castration‐resistant prostate cancer. Phosphorylated IKKα at serine 180 (noncanonical NF‐κB
pathway) and phosphorylated IKKα at threonine 23 correlate with IKKβ (canonical NF‐κB pathway) in the cytoplasm. In addition,
phosphorylated IKKα at threonine 23 correlates with phosphorylated Akt at serine 473 (Akt pathway) in the cytoplasm. Finally, there is a
correlation between IKKα and IKKβ in the nucleus. IKK, inhibitory κ‐B kinase; IKKα, IKK subunits α; IKKβ, IKK subunits β
TABLE 5 Analysis of the effect of clinicopathological parameters, inflammatory features, and IKKα on the survival of castration‐resistant
prostate cancer (n = 115)
Castration‐resistant prostate cancer
Time to death from recurrence
Univariate
HR (95% CI) P
Multivariate
HR (95% CI) P
Clinicopathological parameters
Age (≤70/>70 y) 1.47 (0.90‐2.39) .12 ⋯ ⋯
Gleason score (<7/7/>7) 1.16 (0.69‐1.96) .57 ⋯ ⋯
PSA (≤10 ng/mL/>10 ng/mL) 2.22 (1.14‐4.33) .02* 3.00 (1.02‐8.81) .05
Ki67 (≤1% cells/>1% cells) 2.60 (1.30‐5.20) .01** 2.40 (0.75‐7.66) .14
Inflammatory features (low/high)
CD68+ macrophages 0.34 (0.06‐1.88) .22 ⋯ ⋯
CD8+ T‐cells 1.73 (0.40‐7.44) .46 ⋯ ⋯
CD3+ T‐cells 3.46 (0.73‐16.40) .12 ⋯ ⋯
FOXP3+ T‐cells 0.89 (0.24‐3.38) .87 ⋯ ⋯
IKKα pathway (low/high)
c IKKα 1.65 (0.90‐3.02) .11 ⋯ ⋯
n IKKα 2.60 (1.27‐5.33) .01** 2.50 (0.81‐7.73) .11
c p‐IKKα S180 2.10 (1.17‐3.76) .01** 1.68 (0.69‐4.13) .26
n p‐IKKα S180 1.22 (0.67‐2.20) .51 ⋯ ⋯
c p‐IKKα T23 1.06 (0.59‐1.88) .86 ⋯ ⋯
n p‐IKKα T23 1.10 (0.62‐1.96) .75 ⋯ ⋯
Abbreviations: CI, confidence interval; c/n, citoplasmic/nulcear; HR, hazards ratio; IKK, inhibitory κ‐B kinase; IKKβ, IKK subunit β; NEMO, NF‐κβ essential
modulator; NF‐κβ, nuclear factor κβ; m/c/n, membrane/citoplasmic/nulcear; PSA, prostate‐specific antigen.
*P < .05; **P ≤ .01.
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functionality and make deconvolution of its roles as instigator and/or
responder challenging in an oncogenic setting.36 Several IKKα‐
related interactions drive PC progression, such as the crosstalk be-
tween the canonical and noncanonical NF‐kΒ pathways, and more
importantly, the positive relationship between noncanonical NF‐kΒ
and AR signaling.29 However, how this differs between HNPC and
CRPC is not well understood. To help address this question, this
study utilized patients able to provide both HNPC and CRPC samples
to assess the differences between the two in the same cohort. The
results showed that cytoplasmic IKKα was associated with low AR in
HNPC, where patients presenting high levels of total cytoplasmic
IKKα and low AR protein expression had longer CSS compared with
patients expressing low total cytoplasmic IKKα. Furthermore, low
total cytoplasmic IKKα‐expressing patients with high AR tended to
live longer than those with high levels of total cytoplasmic IKKα,
indicating that IKKα inhibitors could potentially be of benefit to the
latter group. Additionally, we found that the high expression of nu-
clear IKKα and cytoplasmic p‐IKKα S180 was associated with shorter
TTDR in patients with CRPC but was not independently prognostic.
Furthermore, p‐IKKα S180 (noncanonical NF‐kΒ pathway) was cor-
related with IKKβ (canonical NF‐kΒ pathway) in the cytoplasm of
patient with CRPC samples, suggesting interactions between the
canonical and noncanonical pathways. Moreover, cytoplasmic total
IKKα correlated with cytoplasmic IKKβ, indicating that a proportion
of the total IKKα accumulated in the cytoplasm may be involved with
the IKKβ/NEMO complex, which activates the canonical NF‐kΒ
pathway.37 This is not surprising as IKKα is a critical component of
both pathways and suggests that it is acting to drive poor prognosis
via the canonical NF‐kB pathway in CRPC, both directly via the IKK
complex and indirectly through crosstalk with the noncanonical
NF‐kB pathway.
Despite several studies having demonstrated the involvement of
nuclear IKKα in PC progression and metastasis, little is known about
the mechanistic connection between prostate tumorigenesis and
nuclear IKKα activity.19,21,22,33 We found nuclear IKKα correlated
with nuclear NEMO in HNPC, which supports Margalef's report of a
complex comprised of the active isoform of nuclear IKKα (p45‐IKKα)
and nuclear NEMO to prevent apoptosis and sustain tumor growth,
although this study was in colorectal cancer.38 In addition, nuclear
IKKα correlated with nuclear IKKβ in CRPC to drive bad prognosis,
suggesting their crosstalk is through alternative pathways (in-
dependent from NF‐kB pathway). Although IKKα can be distributed
in the cytoplasm as well as in the nucleus, IKKβ is mainly located in
the cytoplasm, although it has also been found to have a nuclear
function that is related to DNA repair.39
Despite the interaction between nuclear IKKα and AR being al-
ready known,40 this is the first study demonstrating a positive cor-
relation between the expression of nuclear p‐IKKα T23 and AR in
HNPC, suggesting crosstalk between these proteins. In addition,
IKKα phosphorylation at T23 by Akt has been described as crucial for
its translocation into the nucleus35 and the correlation we found
between p‐IKKα T23 and Akt in CRPC supports this interaction,
which is consistent with the study by Luo et al who demonstrated
that nuclear IKKα accumulation correlated with the progression and
the clinical grade of PC.21 Interestingly, we observed no correlation
between p‐IKKα T23 and Akt in HNPC, suggesting T23 phosphor-
ylation of IKKα may involve another kinase in this phase of the
disease.
Interestingly, these results also suggest an involvement of
p‐IKKα T23 in the canonical NF‐kΒ pathway, with cytoplasmic p‐IKKα
T23 correlating with IKKβ in the cytoplasm and the nucleus in
patients with CRPC. This is the first study to propose an interaction
between p‐IKKα T23 and IKKβ, potentially via an independent
mechanism, but this requires further investigation.
The activity of IKKα is known to be dependent on molecular and
cellular changes in the tumor microenvironment, including those pro-
moted by therapeutic interventions. The inflammatory response eli-
cited by androgen deprivation promotes the deregulation of several
pathways including NF‐kΒ and is a major contributor to the emergence
of androgen‐independent PC.27,41‐43 Despite most of the studies
analyzing macrophages (CD68+) and lymphocytes (CD3+ and CD8+)
in PC tissues identifying them being protumorigenic,44 their prognostic
relevance is unclear in PC. Therefore, we evaluated the association
between specific immune cells and IKKα expression during the tran-
sition from HNPC to CRPC. The results showed high expression of
cytoplasmic p‐IKKα T23 associated with high CD3+ and CD8+ tumor‐
infiltrated lymphocytes (TILs) in HNPC. On the other hand, high cy-
toplasmic p‐IKKα T23 was associated with low CD3+ TILs and high
macrophage (CD68+) infiltration in CRPC, suggesting the involvement
of macrophages (CD68+) in CRPC progression. Accordingly, macro-
phage infiltration induced by castration45,46 has been related with the
acquisition of CRPC.47,48
Despite IKKα being seen as a key mediator of inflammation and
metastasis in PC, its relationship with cell proliferation remains un-
clear. In this study, we showed that high p‐IKKα T23 nuclear ex-
pression was significantly associated with low Ki67 in CRPC and
allied with better prognosis, suggesting that it is not related to pro-
liferation in PC.
5 | CONCLUSION
In conclusion, we have shown that total cytoplasmic IKKα is poten-
tially a marker for good prognosis for HNPC patients with low AR
expression, and it does not associate with members from the cano-
nical NF‐kB pathway. Furthermore, IKKα is a marker for poor prog-
nosis for patients with CRPC, with nuclear IKKα and cytoplasmic
p‐IKKα S180 associating with shorter TTDR. Cytoplasmic p‐IKKα
S180 also correlate with cytoplasmic IKKβ to drive bad prognosis.
These results suggest that the noncanonical NF‐kB pathway is
dampened by the canonical pathway to promote disease progression.
Taken together, these data indicate that patients with CRPC may
benefit from treatment with IKKα inhibitors if they were to be de-
veloped as therapeutic agents. We note that any expression of IKKα
can be used as an independent prognostic marker, and more studies
will be necessary to further validate and establish whether combining
MONTES ET AL. | 13
IKKα with other markers, such as AR could be used as prognostic
biomarkers.
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